CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression
Shouheng Lin(Chinese Academy of Sciences), Peng Li(Chinese Academy of Sciences), Pentao Liu(Hong Kong Science and Technology Parks Corporation), Baiheng Li(Chinese Academy of Sciences), Duanqing Pei(Westlake University), Yiren Xiao(Chinese Academy of Sciences), Qiuhua Deng(Nanfang Hospital), Qiting Wu(Chinese Academy of Sciences), Yangqiu Li(Jinan University), Muyun Peng(Central South University), Zhesheng Wen(Sun Yat-sen University), Fenglei Yu(Central South University), Yao Yao(Dalian Medical University), Wei Ye(Tongji Hospital), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Simiao Lin(Chinese Academy of Sciences), Donghai Wu(Chinese Academy of Sciences), Guohua Huang(Nanfang Hospital), Suna Wang(National Institutes of Health), Yuchuan Jiang(Sun Yat-sen University), Xinru Wei(China Energy Engineering Corporation (China)), Xuchao Zhang(Guangdong General Hospital), Wei Sun(Zhejiang Wanli University), Qiubin Liang(Guangzhou Institutes of Biomedicine and Health)
Cited by 9
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k